In KRAS-mutant lung cancer, inhibiting MEK increases the expression of TGF-β, IL-6, and IL-23, promoting the differentiation of Th17 cells and the secretion of IL-17 and IL-22, thereby enhancing tumor resistance, invasiveness, and metastasis. Here, IL6 is linked to neoplasm.